Shattuck Labs, Inc.
NASDAQ:STTK · NASDAQ Global Select
+$0.11 today
Vol 1.22M · Avg 0.69M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-59.2%
avg -20.6%
ROIC
-60.7%
avg -52.2%
ROA
-53.6%
avg -41.3%
Analysis
ROA is currently the strongest return metric at -53.6% versus its period average of -41.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Taylor H. Schreiber | Co-Founder, Chief Executive Officer & Director | $876,232.00 | — | 46 | $122,222.00 | 0.26% |
Arundathy Nirmalini Pandite | Chief Medical Officer | $734,899.00 | — | 67 | $166,219.00 | 0.35% |
Andrew R. Neill | Chief Financial Officer | $678,207.00 | — | 40 | $292,251.00 | 0.61% |
Abhinav A. Shukla | Chief Technical Officer | $567,398.00 | — | 53 | $86,380.00 | 0.18% |
Casi DeYoung | Chief Business Officer | $523,482.00 | — | 55 | $73,480.00 | 0.15% |
Kelli Collin | Senior Vice President of Quality | — | — | — | — | — |
Stephen Stout | General Counsel, Corporate Secretary and Chief Ethics & Compliance Officer | — | — | 51 | $93,366.00 | 0.19% |
Thomas Lampkin | Senior Vice President of Regulatory Affairs | — | — | — | — | — |
Brad Huckabee | Vice President of Accounting & SEC reporting | — | — | — | — | — |
Suresh de Silva | Chief Scientific Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
17
$51.20M
Sells
2
$212,544.32
Net Sentiment
+$50.98M
Net buying
Most Active
Ashiya Mona
8 transactions
1–10 of 19
Analysis
Insiders reported 17 buys worth $51.20M and 2 sells worth $212,544.32 over the last 12 months. That adds up to net buying of $50.98M. Ashiya Mona was the most active insider with 8 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -59.6% | +8.7% (8yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at -59.6% over three years. Forward estimates point to Revenue at +8.7% (8yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Ovid Therapeutics Inc.
NASDAQ:OVID
$306.63M
Sutro Biopharma, Inc.
NASDAQ:STRO
$277.15M
Zentalis Pharmaceuticals, Inc.
NASDAQ:ZNTL
$261.61M
Artiva Biotherapeutics, Inc.
NASDAQ:ARTV
$238.39M
InflaRx N.V.
NASDAQ:IFRX
$130.04M
Connect Biopharma Holdings Limited
NASDAQ:CNTB
$125.30M
Kalaris Therapeutics Inc
NASDAQ:KLRS
$88.56M
ImageneBio Inc
NASDAQ:IMA
$63.73M
Context Therapeutics Inc.
NASDAQ:CNTX
$56.26M
Metagenomi, Inc. Common Stock
MGX
$45.74M
Who manages STTK?
Shattuck Labs, Inc. (STTK) lists 10 active executives. The top listed executive is Abhinav A. Shukla, Chief Technical Officer.
Are STTK insiders buying or selling?
Recent insider activity shows net buying of $79.25M.
Explore More
Continue the stock analysis
Jump to another research area for this company.